Robin Dewar

7.9k total citations · 1 hit paper
75 papers, 4.6k citations indexed

About

Robin Dewar is a scholar working on Virology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Robin Dewar has authored 75 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Virology, 57 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in Robin Dewar's work include HIV Research and Treatment (58 papers), HIV/AIDS drug development and treatment (37 papers) and HIV/AIDS Research and Interventions (36 papers). Robin Dewar is often cited by papers focused on HIV Research and Treatment (58 papers), HIV/AIDS drug development and treatment (37 papers) and HIV/AIDS Research and Interventions (36 papers). Robin Dewar collaborates with scholars based in United States, Thailand and Israel. Robin Dewar's co-authors include Julia A. Metcalf, H. Clifford Lane, Richard T. Davey, Michael A. Polis, Joseph A. Kovacs, Frank Maldarelli, Judith Falloon, Ven Natarajan, Joseph W. Adelsberger and John M. Coffin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and The Journal of Experimental Medicine.

In The Last Decade

Robin Dewar

72 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

1999 639 citations Richard T. Davey, Julia A. Metcalf et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Robin Dewar

Since Specialization

Citations

This map shows the geographic impact of Robin Dewar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Dewar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Dewar more than expected).

Fields of papers citing papers by Robin Dewar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Dewar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Dewar. The network helps show where Robin Dewar may publish in the future.

Co-authorship network of co-authors of Robin Dewar

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Dewar. A scholar is included among the top collaborators of Robin Dewar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Dewar. Robin Dewar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Viral Burden and Illness Severity During Acute SARS-CoV-2 Infection Predict Persistent Long COVID Symptoms 2025 ·Open Forum Infectious Diseases ·Elisabeth Brandstetter, Anne Frosch, Kristina S. Burrack, (unknown), R. Jeffrey Goldsmith, Morgan Harris, (unknown), (unknown), (unknown), Robin Dewar, Chetan Shenoy, Irini Sereti, Jason V. Baker	0
2	Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial 2024 ·Critical Care ·Narges Alipanah, (unknown), Kevin Delucchi, Lamorna Brown Swigart, Andrew Willmore, (unknown), Robin Dewar, H. Clifford Lane, Perrine Lallemand, Kathleen D. Liu, Laura J. Esserman, Michael A. Matthay, Carolyn S. Calfee, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	3
3	Impact of Baseline SARS-CoV-2 Load in Plasma and Upper Airways on the Incidence of Acute Extrapulmonary Complications of COVID-19: A Multicentric, Prospective, Cohort Study 2024 ·Clinical Infectious Diseases ·Tomas Ø. Jensen, (unknown), Shaili Gupta, Sean Liu, Nila J. Dharan, Jason V. Baker, Sarah Pett, Kathryn Shaw‐Saliba, Aliasgar Esmail, (unknown), Eyad Almasri, Robin Dewar, Jens Lundgren, David M. Vock	2
4	Plasma SARS-CoV-2 Nucleocapsid Antigen Levels Are Associated With In-hospital Mortality in Hospitalized Patients With COVID-19 2023 ·Kathleen E. Sullivan, (unknown), (unknown), Bruce Thompson, Albert J. Rogers, (unknown), Katherine D. Wick, Neil R. Aggarwal, (unknown), Robin Dewar, (unknown), (unknown), (unknown), Perrine Lallemand, C.T. Hough, (unknown), (unknown)	0
5	Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial 2022 ·Open Forum Infectious Diseases ·(unknown), Alexandra N. Donlan, Z. Jennie, Heather M. Haughey, (unknown), Uma Nayak, Amy J. Mathers, Sylvain Laverdure, Robin Dewar, Patrick Jackson, Scott K. Heysell, Jeffrey M. Sturek, William A. Petri	19
6	Early Presence of HIV-1 Subtype C in Washington, D.C. 2018 ·AIDS Research and Human Retroviruses ·Zehava Grossman, (unknown), (unknown), Wei Shao, Catherine Rehm, Sara R. Jones, Giorgio Bozzi, (unknown), Robin Dewar, Tauseef Ur Rehman, Julia Purdy, Colleen Hadigan, Alice K. Pau, Frank Maldarelli	3
7	Interleukin-15 (IL-15) Strongly Correlates with Increasing HIV-1 Viremia and Markers of Inflammation 2016 ·PLoS ONE ·Sanjay Swaminathan, Ju Qiu, Adam Rupert, Zonghui Hu, Jeanette Higgins, Robin Dewar, Randy Stevens, Catherine Rehm, Julia A. Metcalf, Brad T. Sherman, Michael Baseler, H. Clifford Lane, Tomozumi Imamichi	36
8	Cerebrospinal Fluid HIV-1 Compartmentalization in a Patient With AIDS and Acute Varicella-Zoster Virus Meningomyeloradiculitis 2013 ·Clinical Infectious Diseases ·E. Falcone, (unknown), Virginia Sheikh, Hiromi Imamichi, Robin Dewar, Dima A. Hammoud, Irini Sereti, H. Clifford Lane	13
9	Genotypic Resistance at Viral Rebound Among Patients Who Received Lopinavir/Ritonavir-Based or Efavirenz-Based First Antiretroviral Therapy in South Africa 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·(unknown), Zonghui Hu, Johanna Ledwaba, Lynn Morris, Frank Maldarelli, Robin Dewar, (unknown), (unknown), (unknown), Dean Follmann, Alice K. Pau	13
10	A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda 2010 ·PLoS ONE ·Steven J. Reynolds, Cissy Kityo, Claire W. Hallahan, Geoffrey Kabuye, (unknown), (unknown), Francis Ssali, Robin Dewar, Marybeth Daucher, Richard T. Davey, Peter Mugyenyi, Anthony S. Fauci, Thomas C. Quinn, Mark Dybul	24
11	Interferon-α Produces Significant Decreases in HIV Load 2010 ·Journal of Interferon & Cytokine Research ·Jorge A. Tavel, Chiung‐Yu Huang, (unknown), Julia A. Metcalf, Robin Dewar, Akram Shah, M. B. Vasudevachari, Dean Follmann, Betsey Herpin, Richard T. Davey, Michael A. Polis, Joseph A. Kovacs, Henry Masur, H. Clifford Lane	33
12	Identification and Characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx Recombinant Subtypes in Mali, West Africa 2009 ·AIDS Research and Human Retroviruses ·Hiromi Imamichi, Ousmane Koita, Djénéba Dabitao, (unknown), (unknown), (unknown), Robin Dewar, (unknown), (unknown), Mark Parta, (unknown), Michael A. Polis, H. Clifford Lane, Anatole Tounkara	11
13	ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia 2007 ·PLoS Pathogens ·Frank Maldarelli, Sarah Palmer, Martin King, Ann Wiegand, Michael A. Polis, JoAnn M. Mican, Joseph A. Kovacs, Richard T. Davey, (unknown), Robin Dewar, Shuying Liu, Julia A. Metcalf, Catherine Rehm, Scott C. Brun, George J. Hanna, Dale J. Kempf, John M. Coffin, John W. Mellors	267
14	Increasing CD4 ⁺ T Cells Specific for Tuberculosis Correlate with Improved Clinical Immunity after Highly Active Antiretroviral Therapy 2002 ·AIDS Research and Human Retroviruses ·Richard L. Hengel, Maria C. Allende, Robin Dewar, Julia A. Metcalf, JoAnn M. Mican, H. Clifford Lane	17
15	Comparative Analysis of HIV-1 Viral Load Assays on Subtype Quantification: Bayer Versant HIV-1 RNA 3.0 Versus Roche Amplicor HIV-1 Monitor Version 1.5 2002 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Tarek Elbeik, W. Gregory Alvord, Rapee Trichavaroj, Mark de Souza, Robin Dewar, Arthur E. Brown, David Chernoff, Nelson L. Michael, Patricia Nassos, Keith Hadley, Valerie L. Ng	52
16	Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy 2001 ·European Journal of Immunology ·Joseph A. Kovacs, Susan Vogel, (unknown), (unknown), Randy Stevens, Joseph W. Adelsberger, Richard A. Lempicki, Richard L. Hengel, Irini Sereti, (unknown), Robin Dewar, Richard T. Davey, Robert Walker, J Falloon, Michael A. Polis, Henry Masur, H. Clifford Lane	48
17	Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV 2001 ·The Journal of Experimental Medicine ·Joseph A. Kovacs, Richard A. Lempicki, Igor A. Sidorov, Joseph W. Adelsberger, Betsey Herpin, Julia A. Metcalf, Irini Sereti, Michael A. Polis, Richard T. Davey, Jorge A. Tavel, Judith Falloon, Randy Stevens, (unknown), Robin Dewar, Douglas J. Schwartzentruber, Miriam R. Anver, Michael Baseler, Henry Masur, Dimiter S. Dimitrov, H. Clifford Lane	181
18	Effects of Intermittent Interleukin‐2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi‐Species Expression 2000 ·The Journal of Infectious Diseases ·Joseph A. Kovacs, Hiromi Imamichi, Susan Vogel, Julia A. Metcalf, Robin Dewar, Michael Baseler, Randy Stevens, Joseph W. Adelsberger, Laurie Lambert, Richard T. Davey, Robert Walker, Judith Falloon, Michael A. Polis, Henry Masur, H. Clifford Lane	25
19	Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4 ⁺ and CD8 ⁺ T cell turnover in HIV-infected patients 2000 ·Proceedings of the National Academy of Sciences ·Richard A. Lempicki, Joseph A. Kovacs, Michael Baseler, Joseph W. Adelsberger, Robin Dewar, Ven Natarajan, Marjorie Bosche, Julia A. Metcalf, Randy Stevens, (unknown), W. Gregory Alvord, Michael A. Polis, Richard T. Davey, Dimiter S. Dimitrov, H. Clifford Lane	158
20	The Effect of Thalidomide on the Pathogenesis of Human Immunodeficiency Virus Type 1 and M. tuberculosis Infection 1996 ·Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Jeffrey D. Klausner, Sanit Makonkawkeyoon, Pasakorn Akarasewi, Koh Nakata, Watchara Kasinrerk, Laura G. Corral, Robin Dewar, H. Clifford Lane, Victoria H. Freedman, (unknown)	135

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact